Abstract:Abstract Background Predicting the response of patients with ulcerative colitis (UC) to a molecular targeted drug before administration is an unmet need for optimizing individual patient care. We hypothesized that a new machine-learning approach could identify predictors of therapeutic efficacy that have not been reported as statistically significant factors using the conventional statistical approaches. As a proof-of-concept study, we explored predictors and a prediction model for the efficacy of vedolizumab (VDZ) for UC. Methods The clinical data at baseline (week 0) of 34 UC patients who started VDZ at Kyorin University Hospital was collected (Cohort 1; training cohort). The collected data contained 49 clinical features; patient background (e.g. sex, age, disease phenotype, etc.), treatment history, clinical/endoscopic activity, and blood examination items. Random forest (RF) was employed to investigate clinical features that affect steroid-free clinical remission (SFCR) with VDZ at week 22 in UC. A prediction model was developed using logistic regression based on the results of RF. The prediction ability of the prediction model was evaluated with the data of 35 patients who started VDZ at Toho University Sakura Medical Center (Cohort 2; extra-facility test cohort). The prediction ability of the VDZ prediction model for ustekinumab (UST) was examined using the data of 22 patients who started UST at Kyorin University Hospital (Cohort 3). Results RF computed the contribution of each clinical feature to achievement/no-achievement of SFCR at week 22. When the top 8 features (partial Mayo score, MCH, BMI, BUN, concomitant use of AZA, lymphocyte fraction, height, and CRP) were employed for logistic regression, the prediction accuracy of the prediction model was 100% and 68.6% for Cohorts 1 and 2, respectively. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in Cohort 2 were 92.3%, 54.5%, 54.5%, and 92.3%, respectively. Meanwhile, in Cohort 3 with UST, sensitivity, specificity, PPV and NPV were 70.0%, 45.5%, 53.4%, and 62.5%, respectively. Conclusion Our machine-learning approach detected clinical features at baseline that impact the achievement of SFCR at week 22 in patients who received VDZ for UC and developed a prediction model that appears to be useful to screen non-responders to VDZ. Given the low prediction ability in Cohort 3, our findings support the notion that a prediction model for each molecular targeted drug is needed for optimizing the drug selection for individual patients. This study provides the proof-of-concept that machine learning on clinical data could open a new era of personalized medicine for UC.

Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data

Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation

A protocol for the development and internal validation of a model to predict clinical response to antihistamines in urticaria patients

Clinical risk prediction with random forests for survival, longitudinal, and multivariate (RF-SLAM) data analysis

Predicting Time to Diabetes Diagnosis Using Random Survival Forests

P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline

Using Random Effects Machine Learning Algorithms to Identify Vulnerability to Depression

Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria

Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

[Random Survival Forest: Applying Machine Learning Algorithm in Survival Analysis of Biomedical Data].

Predictors of treatment response in chronic spontaneous urticaria

Prediction of emergency department presentations for acute coronary syndrome using a machine learning approach

Random survival forests for dynamic predictions of a time-to-event outcome using a longitudinal biomarker

Predicting the Prognosis of Patients in the Coronary Care Unit: A Novel Multi-Category Machine Learning Model Using XGBoost

Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis

Long-term survival and second malignant tumor prediction in pediatric, adolescent, and young adult cancer survivors using Random Survival Forests: a SEER analysis

Development and validation of novel interpretable survival prediction models based on drug exposures for severe heart failure during vulnerable period

Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning

Cardiovascular Event Prediction by Machine Learning: The Multi-Ethnic Study of Atherosclerosis

Random Forest-Based Prediction of Stroke Outcome

Predicting Treatment Initiation from Clinical Time Series Data via Graph-Augmented Time-Sensitive Model